Table 6 KRAS and PIK3CA mutations in cervical cancer

Dokianakis et al. [50]^a

0/10 (0%)¹

–

2/2 (100%)¹

–

Stenzel et al. [51]^b

3/22 (13.6%)²

–

1/2 (50.0%)²

–

Pappa et al. [52]^a

2/28 (7.1%)³

–

1/19 (5.3%)³

–

Miyake et al. [53]^c

–

2/12 (16.7%)ⁱ

–

1/9 (11.1%)ⁱ

Cui et al. [38]^d

–

5/84 (6.0%)ⁱⁱ

–

10/100 (10.0%)ⁱⁱ

Iida et al. [18]^c

0/32 (0%)⁴

–

3/48 (6.3%)⁴

–

Janku et al. [54]^e

–

ⁱ2/8 (25.0%)

–

0/7 (0%)ⁱ

Janku et al. [55]^e

1/10 (10%)⁴

5/14 (35.7%)ⁱ

–

–

Janku et al. [40]^e

–

6/18 (33.3%)ⁱ

–

–

Wright et al. [19]^e

0/40 (0%)⁵

15/40 (37.5%)ⁱⁱⁱ

7/40 (17.5%)⁵

10/40 (25.0%)ⁱⁱⁱ

McIntyre et al. [39]^f

–

16/69 (23.2%)ⁱ

–

3/13 (23.1%)ⁱ

Ojesina et al. [48]^g

1/79 (1.3%)⁶

9/79 (11.4%)^iv

2/35 (5.7%)⁶

8/35 (22.9%)^iv

Rashmi et al. [32]^e

–

6/120 (5.0%)ⁱⁱⁱ

–

2/20 (10.0%)ⁱⁱⁱ

Spaans et al. [47]^h

9/205^ns (4.4%)⁵

50/205^ns (24.4%)ⁱⁱⁱ

Ns

Ns

Tornesello et al. [56]ⁱ

–

3/55 (5.5%)^v

–

–

The present study^j

0/91 (0%)⁷

19/95 (20.0%)^vi

–

–